Sirtris Pharmaceuticals: Novel, Potent SIRT1 Activator Reduces Fat, Boosts Endurance and Improves Insulin Sensitivity in a Pre-clinical Model of Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that one of its new chemical entities, which is structurally unrelated to and one thousand times more potent than resveratrol, reduces fat, boosts exercise endurance and improves insulin sensitivity in mice on a high-fat diet.
MORE ON THIS TOPIC